Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns

Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns AbstractGadolinium-based contrast agents have been used for magnetic resonance imaging (MRI) examinations since the late 1980s with an excellent overall cumulative safety record. Initially favored for use in patients with renal impairment because of lack of significant nephrotoxic effect at clinical doses, in 2006, multiple reports convincingly linked the rare but serious disease nephrogenic systemic fibrosis to the administration of gadolinium-based contrast agents in patients with severe renal failure. This in turn led to new policies on administration of these agents, resulting in changes in practice patterns that have virtually resulted in the elimination of the disease after the year 2009. The purpose of this review is to summarize the factors that led to the emergence of nephrogenic systemic fibrosis, including the risk associated with different types of contrast agents based on their stability, and the changes in practice patterns and usage of gadolinium-based contrast agents in recent years that have been mainly driven by the discovery and association with nephrogenic systemic fibrosis. The article will conclude with a brief overview of new emerging safety concerns that could further impact the use of this class of contrast agents and impact practice patterns in the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Topics in Magnetic Resonance Imaging Wolters Kluwer Health

Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns

Forghani, Reza
Topics in Magnetic Resonance Imaging , Volume 25 (4) – Aug 1, 2016
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/adverse-effects-of-gadolinium-based-contrast-agents-changes-in-MM9YSsbWQ5

References (56)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0899-3459
eISSN
1536-1004
DOI
10.1097/RMR.0000000000000095
pmid
27367314
Publisher site
See Article on Publisher Site

Abstract

AbstractGadolinium-based contrast agents have been used for magnetic resonance imaging (MRI) examinations since the late 1980s with an excellent overall cumulative safety record. Initially favored for use in patients with renal impairment because of lack of significant nephrotoxic effect at clinical doses, in 2006, multiple reports convincingly linked the rare but serious disease nephrogenic systemic fibrosis to the administration of gadolinium-based contrast agents in patients with severe renal failure. This in turn led to new policies on administration of these agents, resulting in changes in practice patterns that have virtually resulted in the elimination of the disease after the year 2009. The purpose of this review is to summarize the factors that led to the emergence of nephrogenic systemic fibrosis, including the risk associated with different types of contrast agents based on their stability, and the changes in practice patterns and usage of gadolinium-based contrast agents in recent years that have been mainly driven by the discovery and association with nephrogenic systemic fibrosis. The article will conclude with a brief overview of new emerging safety concerns that could further impact the use of this class of contrast agents and impact practice patterns in the future.

Journal

Topics in Magnetic Resonance Imaging – Wolters Kluwer Health

Published: Aug 1, 2016

There are no references for this article.